Abstract
Of 4257 patients with gestational trophoblastic disease (GTD) registered between 1986 and 1996 with the Trophoblastic Screening and Treatment Centre, Sheffield, 231 women required chemotherapy; 28 were treated 24 weeks or more after the initial evacuation of products of conception. In 18 patients late treatment was a result of a predetermined watch and wait policy on the part of the Centre; these patients formed the study group. Patients were identified from the Centre's computer database. The time interval from first evacuation (diagnosis) to start of chemotherapy was calculated for each patient. Hospital records were reviewed when the interval of observation was 24 weeks or greater to determine patient characteristics, treatment and outcome. Eighteen women were treated ‘late’ (according to Centre policy), with a median age of 30 years (range 21–57 years). The interval from diagnosis to treatment ranged from 24 to, in one case, 56 weeks (median 33 weeks). Fourteen of 18 women had complete moles, 3/18 had partial moles and one had unclassified disease. All women had low-risk disease and were treated with single-agent methotrexate; 17 were cured with this regimen, one also required salvage chemotherapy. In conclusion, where a successful surveillance programme is in operation for GTD, a wait and watch policy can be adopted without compromising patients whose definitive treatment is commenced more than 6 months after the initial diagnosis. © 2000 Cancer Research Campaign
Keywords: trophoblastic disease, late treatment, molar pregnancy
Full Text
The Full Text of this article is available as a PDF (57.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bagshawe K. D. Risk and prognostic factors in trophoblastic neoplasia. Cancer. 1976 Sep;38(3):1373–1385. doi: 10.1002/1097-0142(197609)38:3<1373::aid-cncr2820380342>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
- Gillespie A. M., Lorigan P. C., Radstone C. R., Waterhouse J. C., Coleman R. E., Hancock B. W. Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate. Br J Cancer. 1997;76(10):1382–1386. doi: 10.1038/bjc.1997.564. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lurain J. R., Brewer J. I., Torok E. E., Halpern B. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol. 1983 Mar 1;145(5):591–595. doi: 10.1016/0002-9378(83)91202-4. [DOI] [PubMed] [Google Scholar]
- Rustin G. J., Newlands E. S., Lutz J. M., Holden L., Bagshawe K. D., Hiscox J. G., Foskett M., Fuller S., Short D. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol. 1996 Oct;14(10):2769–2773. doi: 10.1200/JCO.1996.14.10.2769. [DOI] [PubMed] [Google Scholar]
- Rustin G. J., Pektasides D., Bagshawe K. D., Newlands E. S., Begent R. H. Fertility after chemotherapy for male and female germ cell tumours. Int J Androl. 1987 Feb;10(1):389–392. doi: 10.1111/j.1365-2605.1987.tb00208.x. [DOI] [PubMed] [Google Scholar]
- Sharma S., Jagdev S., Coleman R. E., Hancock B. W., Lorigan P. C. Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. Br J Cancer. 1999 Nov;81(6):1037–1041. doi: 10.1038/sj.bjc.6690804. [DOI] [PMC free article] [PubMed] [Google Scholar]